Jun 4, 2012 - (58) Field of Classification Search. (56) ... cell proliferative disorders by administration of a Syk kinase ... Sheet 3 of26 ..... survival data is for NOD-SCID mice injected intravenously ..... marrow, undergo a series of cell divisions to form multipotent ... compared to wild-type) in the activation loop of the second.
111111
(12)
(54)
(10)
Masuda et al.
(45)
METHODS OF TREATING CELL PROLIFERATIVE DISORDERS Inventors: Esteban Masuda, Menlo Park, CA (US); Donald G. Payan, Hillsborough, CA (US); Elliot B. Grossbard, San Francisco, CA (US); Somasekhar Bhamidipati, Foster City, CA (US); Rajinder Singh, Belmont, CA (US)
(73)
Assignee: Rigel Pharmaceuticals, Inc., South San Francisco, CA (US) Notice:
Subject to any disclaimer, the terrIl of this patent is extended or adjusted under 35 U.S.c. 154(b) by 0 days. This patent is subject to a terminal disclaimer.
(21)
(22)
Filed:
Prior Publication Data Sep. 27, 2012
Related U.S. Application Data (63)
Continuation of application No. 111407,233, filed on Apr. 18,2006, now Pat. No. 8,227,455.
(60)
Provisional application No. 60/672,648, filed on Apr. 18, 2005, provisional application No. 601706,710, filed on Aug. 8, 2005.
(51)
Int. Cl. A61K 31/33 (2006.01) U.S. Cl. USPC .......................................................... 5141183 Field of Classification Search USPC .......................................................... 5141183 See application file for complete search history.
(58)
7,884, III B2 Al Al Al Al Al Al Al Al Al Al Al
WO WO WO WO WO WO WO WO
(56)
References Cited
5,958,935 5,985,856 6,593,326 7,449,458 7,538,108
Argade et al. Gillman et al. Argade et al. Mehta et al. Singh et al. Singh et al. Singh et al. Masuda et al. Singh et al. 112008 Argade et al. 112008 Argade et al. 212009 Hitoshi et al.
212011 1012003 512005 8/2005 912005 1012005 9/2006 1212006 312007
FOREIGN PATENT DOCUMENTS 00/39101 7/2000 02/059110 03/026664 03/030909
2004014832 2005/016893
2005013996 2006068770
8/2002 4/2003 4/2003 212004 212005 212005 6/2006
OTHER PUBLICATIONS
Jun. 4, 2012
US 2012/0245127 Al
Patent No.: US 8,481,521 B2 Date of Patent: *Jul. 9,2013
2003/0195169 2005/0113398 2005/0171171 2005/0209224 2005/0234049 2006/0211657 2006/0276459 2007/0060603 2008/0009484 2008/0021020 2009/0048214
Appl. No.: 13/487,979
(65)
(52)
US008481521B2
United States Patent
(75)
( *)
1111111111111111111111111111111111111111111111111111111111111
U.S. PATENT DOCUMENTS A 911999 Davis et al. A 1111999 Stella et al. Bl 7/2003 Bradbury et al. B2 1112008 Bhamidipati et al. B2 5/2009 Singh et al.
Talmadge, James E., et ai, "Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer," The American Journal of Pathology, Mar. 2007, vol. 170, No.3, pp. 793-804. Suggitt, Marie, et ai, "50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches," Clinical Cancer Research, Feb. 1,2005, vol. 11, pp. 971-981. U.S. Appl. No. 111567,780, filed Dec. 7, 2006. Pine et aI., "An Orally Bioavailable Inhibitor of FLT3 and Syk Kinases Prevents Tumor Growth in Subcutaneously Implanted Human Tumor Xenografts and Promotes Cell Death in FLT3 Mutant AML Cells," Blood (ASH Annual Meeting Abstracts), vol. 106, Abstract 243, 2005. Hoelzer. et al., "Recent Approaches in Acute Lymphoblastic Leukemia in Adults," Critical Reviews in Oncology/Hematology, vol. 36, p. 49-58,2000.
Primary Examiner - Brandon Fetterolf Assistant Examiner - Christopher R Stone (74) Attorney, Agent, or Firm - McDounell Boehnen Hulbert & Berghoff LLP (57)
ABSTRACT
The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis. 18 Claims, 26 Drawing Sheets
~
00 • ~
~
~
~
= ~
COMPOUND VI
DMSO 01 51.6 S/G2 48.4
STI a'
G1
:-
3.6
SlG2
~'-CI
N
o
....
TEUSyk
(.H
A
o
1000
2000
3000
4000
I • • • ,'''''' • ;
0
1000
4
2000
4
;
•
..
3000
~
••
\i>U8'fJ
4000
rJ)
G1 70.71
A
5/G2 29.3
01 95,41 S/G2 4.6
.....
0
bcr/abl
~
=.... ....
('D ('D
L 0
N 0\
1000
2000
3000
4000
0
1000
2000
3000
4000
0
1000
2000
3000
4000
DNA
1
d
rJl QO
~
QO
"""'" 11. N
= """'"
N
~
00 • ~
~
~
~
= ~
GFP
TEL-Syk
BCR-Abl
- - - 10000·'T"'""i- - - , r - - - - 14.7
19.9
a'
:~'-CI
N
o
....
1
(.H
rJ)
=-
('D ('D
.....
N
a. u...
, 10
(!)
kaO.D8
100
1000 10000
.
t ••••• ,
10
100
,. ..
'IIIl'·-'
1000 10000
....
o
14.1
• '. '1
1
10
100
1000 10000
N 0\
.1 d
rJl QO
~
QO
"""'" 11. N
= """'"
N
u.s. Patent
Jul. 9,2013
-
le/)
>------.. Q Z
:l
o a..
:it
0"------
o
.x:
>.
(f) I
...J
W
I-
Sheet 3 of26
US 8,481,521 B2
u.s. Patent
Jul. 9,2013
US 8,481,521 B2
Sheet 4 of26
e e
,.e ,...
e e
IiO
e
I'-
.J
I
i
.
e e
"It
e e('II e
e
r.g ,... , e e
IiO
t'-j
-....J+
e e (Q e ~ e e('II e
() CJ)
lJ.
d:lf)
0... LL
(!)
u
~
~
uI
~
00 • ~
~
~
~
= ~
DiV1S0
G1 ..
~
COMPOUND VI
G1 66,4; 8102 33.6
I
=
STI
G1 93_61 S/02 6.4
!
:~'-CI
Gt67.91 SlG2 ~32.1
N 0
....
(.H
rJ)
--o
=-
('D ('D
U'J
.....
Ul
Q)
200 ""'-------1....
300
400
0
100
200
300
400
0
100
200
300
400
....
o
N 0\
DNA d
rJl QO
~
QO
"""'" 11. N
= """'"
N
u.s. Patent
Jul. 9,2013
US 8,481,521 B2
Sheet 6 of26
c c
~
c c
C
M
~
C C C N C C
C ,... C C
c e
5
"II'
0
C C
c
Z
M
::> 0
C C
c
a.
N
:i
u..
c c c
0
....
0
c
t.O
$ 0
~ Q
N l!)
iii
c c c
"II' C
c c
M
c c c
N
C
O~~Z ·c
CJ
(fJ
t.n
Cl'l fl.
N
(.0
sueo
u.s. Patent
Jul. 9,2013
Sheet 7of26
fA
i6 (.)
